An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet Syndrome
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 62
- 试验地点
- 18
- 主要终点
- Safety and Tolerability of single and multiple doses of STK-001 with respect to:
研究概览
简要总结
Stoke Therapeutics is evaluating the safety and tolerability of single and multiple ascending doses of STK-001 in patients with Dravet syndrome. Change in seizure frequency, overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.
详细描述
STK-001 is an investigational new medicine for the treatment of Dravet syndrome. STK-001 is an antisense oligonucleotide (ASO) that is intended to increase the level of productive SCN1A messenger RNA (mRNA) and consequently increase the expression of the sodium channel Nav1.1 protein. This RNA-based approach is not gene therapy, but rather RNA modulation, as it does not manipulate nor insert genetic deoxyribonucleic acid (DNA).
STK-001 is designed to upregulate Nav1.1 protein expression from the nonmutant (wild-type) copy of the SCN1A gene to restore physiological Nav1.1 levels. Nav1.1 levels are reduced in people with Dravet syndrome. Stoke has generated preclinical data demonstrating proof-of-mechanism for STK-001.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of Dravet Syndrome (DS) with onset of recurrent focal motor or hemiconvulsive or generalized tonic-clonic seizures prior to 12 months of age, which are often prolonged and triggered by hyperthermia.
- •No history of causal MRI lesion
- •No other known etiology
- •Normal development at seizure onset.
- •Documented pathogenic, likely pathogenic variant, or variant of uncertain significance in the SCN1A gene associated with DS.
- •Use of at least 2 prior treatments for epilepsy that either had lack of adequate seizure control (requiring an additional AED) or had to be discontinued due to an AE(s).
- •Currently taking at least one AED at a dose which has been stable for at least 4 weeks prior to Screening.
- •Stable epilepsy medications or interventions for epilepsy (including ketogenic diet or vagal nerve stimulator) for at least 4 weeks prior to Screening.
排除标准
- •Known pathogenic mutation in another gene that causes epilepsy
- •Currently treated with an AED acting primarily as a sodium channel blocker, as maintenance treatment, including: phenytoin, carbamazepine, oxcarbazepine, lamotrigine, lacosamide, or rufinamide.
- •Clinically significant unstable medical conditions other than epilepsy.
- •Clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to Screening or prior to dosing on Day 1, other than epilepsy.
- •History of brain or spinal cord disease (other than epilepsy or DS), or history of bacterial meningitis or brain malformation
- •Spinal deformity or other condition that may alter the free flow of cerebrospinal fluid (CSF) or has an implanted CSF drainage shunt.
- •Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, may influence the results of the study, or may affect the patient's ability to participate in the study.
研究组 & 干预措施
Single Ascending Doses
Enrollment of patients in two age groups. A Sentinel group of 2 patients aged 13 to 18 years of age, inclusive, and an expanded group of 2 patients 2 to 12 years of age to receive single doses. There will be an option to dose up to 6 additional patients at each dose level and an option to expand the maximum tolerated dose level with 5 additional patients.
干预措施: STK-001 - Single Ascending Doses (Drug)
Multiple Ascending Doses
Enrollment of patients in two age groups. A Sentinel group of 2 patients aged 13 to 18 years of age, inclusive, and an expanded group of 2 patients 2 to 12 years of age to receive multiple doses. There will be an option to dose up to 6 additional patients at each dose level and an option to expand the maximum tolerated dose level with 10 additional patients.
干预措施: STK-001 - Multiple Ascending Doses (Drug)
结局指标
主要结局
Safety and Tolerability of single and multiple doses of STK-001 with respect to:
时间窗: Screening (Day -28) until 6 months after single and multiple drug dosing
1. Incidence of adverse events 2. incidence of abnormal vital signs 3. Abnormal physical examination findings 4. Abnormal 12-lead electrocardiogram (ECG) 5. Abnormal laboratory parameters
Pharmacokinetic (PK) Parameters
时间窗: Day 1 (Dosing) until 6 months after single and multiple drug dosing
Analysis of plasma concentrations of STK-001
Exposure of STK-001 in Cerebrospinal Fluid (CSF)
时间窗: Day 1 (Dosing) until 6 months after single and multiple drug dosing
Measurement of STK-001 concentrations
次要结局
- Measurement of seizure frequency(Screening (Day -28) until 6 months after single and multiple drug dosing)
- Change in Caregiver Global Impression of Change Scale(Baseline (Day -1) until 6 months after single and multiple drug dosing)
- Change in Clinician-assessed Global Impression of Change Scale(Baseline (Day -1) until 6 months after single and multiple drug dosing)
- Measurement of Quality of Life(Baseline (Day -1) until 6 months after single and multiple drug dosing)